Arthritis & Rheumatism · 1975 · 102 citations · 24 references
MedicineClinical SciencesPharmacotherapyAutoimmunityImmunopathologyRheumatologyAutoimmune DiseasesAutoimmune Rheumatic DiseasesImmunosuppressionRenal DiseaseSystemic Lupus ErythematosusAzathioprine UsePrednisone UseSystemic Lupus Erythematosus Associations
One hundred ten patients with systemic lupus erythematosus (SLE) were classified into two groups, patients with central nervous system (CNS) or severe renal disease (usually associated with a poor prognosis) and patients without these manifestations, to define criteria for azathioprine therapy. Fifty-four of 68 patients with a poor prognosis received azathioprine. Azathioprine-treated patients showed improved long-term survival (72% vs 29%, P less than .005) and fewer hospitalizations (0.24/patient-years vs 0.89/patient-years, P less than .001). Azathioprine therapy in 19 of 42 patients with a good prognosis was associated with fewer hospitalizations (.02/patient-years vs .17/patient-years, P less than .05), but no decrease in maintenace prednisone requirement. Progression from a good to a poor prognosis was less frequent (1 of 20 vs 11 of 34, P = less than .05) among azathioprine-treated patients. Toxicity of azathioprine was minimal. Azathioprine therapy is indicated in patients with CNS or severe renal disease, and in patients whose prognosis was good with frequent hospitalizations or a maintenance prednisone requirement greater than 15 mg/day.
24
DE-NOVO BRAIN TUMOURS IN RENAL-TRANSPLANT RECIPIENTS
S. A. Schneck, Israel Penn · The Lancet · 1971 · 258 citations
Medicine, Nephrology, Oncology +10
Reticulum Cell Sarcoma after Renal Homotransplantation and Azathioprine and Prednisone Therapy
P. B. Doak, John Z. Montgomerie, J. D. K. North et al. · BMJ · 1968 · 163 citations · Full text
Medicine, Nephrology, Oncology +13